rist4721
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 13, 2019 (NCT03988335)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor BINHIBITOR
CXCR2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05448391 | Phase 2 | Sep 13, 2022 | Aristea Therapeutics, Inc. |
| NCT05348681 | Phase 2 | Jul 18, 2022 | Aristea Therapeutics, Inc. |
| NCT05194839 | Phase 2 | Jan 5, 2022 | Aristea Therapeutics, Inc. |
| NCT04105959 | Phase 1 | Aug 28, 2019 | Aristea Therapeutics, Inc. |
| NCT03988335 | Phase 2 | Feb 13, 2019 | Aristea Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aristea Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2019 |
1 organizations
Page 1 / 1